Not feeling okay recently? With a SPRAVATO® at Elite Pain Management and Recovery Centers, with location in Springfield, Missouri. To learn more about it has to offer, call or book your visit online.
SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor. It is a first-of-its kind medicine approved by the FDA in two major depressive disorder (MDD) subpopulations with high unmet need.
SPRAVATO® is approved in the United States, in conjunction with an oral antidepressant, to treat adults with treatmentresistant depression (TRD) and to treat depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® REMS. A REMS program is in place to ensure the safety of all patients who are treated with SPRAVATO®. The goals of the REMS are to mitigate the risks of serious adverse outcomes resulting from sedation and dissociation caused by SPRAVATO® administration, and abuse and misuse of SPRAVATO®, by
first visit may be a consultation to discuss the details with a healthcare provider at the certified SPRAVATO® treatment center to determine if SPRAVATO® is considered an appropriate treatment option. If SPRAVATO® is recommended, the healthcare provider will discuss important safety risks and enroll patients in the SPRAVATO® REMS Program prior to treatment initiation.
SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:
• Adults with treatment-resistant depression (TRD)
• Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not
take part in these activities until the next day following a restful sleep. See “What is the most important information I
should know about SPRAVATO®?”
SPRAVATO® may cause serious side effects including:
• See “What is the most important information I should know about SPRAVATO®?”
• Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.
• Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.
• Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.
• feeling disconnected from yourself, your thoughts, feelings and things around you
• decreased feeling of sensitivity (numbness)
• feeling anxious
• lack of energy
• feeling sleepy
• spinning sensation
• increased blood pressure
• feeling drunk
• feeling very happy or excited